Biomarkers
Prognostic Value of the HALP Score in Metastatic Mesothelioma: A Retrospective Study
Oncology 2025 July 8 [Link] Ozlem Dogan, Yakup Duzkopru, Tulay Eren Abstract Background: Malignant mesothelioma is a rare but aggressive cancer with limited treatment options and poor prognosis. Hemoglobin, Albumin, Lymphocyte, Platelet(HALP) score , reflecting inflammation and nutritional status, is a potential prognostic marker in various cancers. Our study aims to investigate the prognostic value…
Read MoreImmune Composition and Immunotherapy Outcomes of Mesothelioma with BAP1, CDKN2A, MTAP, and NF2 Alterations
Journal of Thoracic Oncology 2025 June 25 [Link] Ibiayi Dagogo-Jack, Owen Mitchell, Elizabeth Codd, Annie Li, Dawn Mitchell, Samantha E Flynn, Nanna Sivamanoharan, Patrick Reeves, Mark Poznansky, Ivan Valiev, Artem Kosmin, Beow Y Yeap, Grace Hambelton, A John Iafrate, Jochen K Lennerz, Yin P Hung, Hedy Kindler Abstract Background: First-line mesothelioma treatment paradigms prioritize histology…
Read MoreHMGB1 as a Key Mediator in Malignant Mesothelioma and a Potential Target for Asbestos-Related Cancer Therapy
Toxics 2025 May 28 [Link] Yi-Fang Zhong, Chan Ding, Chun-Ji Yao, Jia-Chun Wang, Min-Qian Feng, Xiao-Xue Gong, Lin Yu, Hua-Dong Xu, Hai-Ling Xia Abstract Malignant mesothelioma (MM) is a highly aggressive cancer strongly associated with asbestos exposure, and accumulating evidence suggests that high mobility group box 1 (HMGB1) plays a central role in its pathogenesis.…
Read MoreLoss of MTAP expression is not an accurate surrogate for CDKN2A homozygous deletions in peritoneal mesothelioma
Histopathology 2025 June 25 [Link] Andrea Quaranta, Andrea Marzullo, Francesco Fortarezza, Sonia Maniglio, Concetta Caporusso, Floriana Pentimone, Federica Pezzuto, Domenica Cavone, Teresa Lettini, Mario Magistro, Cecilia Salzillo, Luigi Vimercati, Paolo Graziano, Gabriella Serio, Antonio d’Amati Abstract Aims: Mesothelioma is a malignant neoplasm of the serosal membranes originating from mesothelial cells. Peritoneal mesothelioma is the second…
Read MorePBK Expression Promotes the Aggressive Phenotypes of Mesothelioma
Cancer Science 2025 June 24 [Link] Kazumi Hori, Ichidai Tanaka, Tatsuhiro Sato, Mika Sato, Yuta Kodama, Hideyuki Itoigawa, Yuichi Abe, Taketo Kato, Ayumu Taguchi, Mitsuo Sato, Yoshitaka Sekido, Toyofumi Fengshi Chen-Yoshikawa, Makoto Ishii Abstract Mesothelioma is one of the most aggressive neoplasms worldwide that has a particularly poor prognosis. We have previously discovered that oxytocin…
Read MoreFibulin-3 in plasma and pleural effusion as a biomarker of mesothelioma
Radiology and Oncology 2025 June 16 [Link] Katja Adamic, Mateja Marc Malovrh, Urska Bidovec Stojkovic, Ales Rozman Abstract Background: Malignant pleural mesothelioma (MPM) is a global health concern linked to asbestos exposure. In Slovenia, regions with high asbestos exposure rates make MPM a significant public health issue. Although thoracoscopic biopsy is the gold standard for…
Read MoreIdentification of a novel prognostic gene signature in pleural mesothelioma: a study based on The Cancer Genome Atlas database and experimental validation
Translational Cancer Research 2025 May 30 [Link] Xinmeng Wang, Yongqin Yang, Wenzhong Yang, Xi Yang, Jinsong Li, Yaru Lin, Zhengliang Li, Jiangyan Li, Wei Xiong Abstract Background: Early detection and prognostic prediction are crucial in improving the survival of patients with pleural mesothelioma (PM). Therefore, this study aimed to develop a gene prognostic risk model…
Read MoreExpression of Heart Development Protein With EGF-Like Domains 1 (HEG1) Decorated With Low-Sulfated Keratan Sulfate in Human Malignant Pleural Mesothelioma
Pathology International 2025 June 17 [Link] Koki Nakashima, Hitomi Hoshino, Zui Zhang, Tomoya O Akama, Nobuyuki Kondo, Seiki Hasegawa, Yoshitaka Sekido, Mana Fukushima, Tamotsu Ishizuka, Motohiro Kobayashi Abstract The glycoform of heart development protein with EGF-like domains 1 (HEG1) recognized by the SKM9-2 monoclonal antibody is a useful diagnostic marker for malignant pleural mesothelioma (MPM).…
Read MoreExploration of the anticancer properties of Caffeic Acid in malignant mesothelioma cells
Medical Oncology 2025 June 10 [Link] Dayk Muratoglu, Gulseren Turhal, Busra Demirkan, Izel Nermin Baslilar Nimet Sule Yuncu, Asuman Demiroglu-Zergeroglu Abstract Malignant Pleural Mesothelioma (MPM) is the most prevalent type of Mesothelioma and currently has no effective treatment options. This underscores the urgent need to explore new therapeutic agents and innovative strategies. Phenolic acids are…
Read MoreImmune-related gene risk model establishment and role of key gene FUCA1 in malignant pleural mesothelioma
Frontiers in Pharmacology 2025 May 23 [Link] Lin Shi, Dongqi Yuan, Fuyi Zhu, Yuchao He, Ran Zuo, Liwei Chen, Yi Luo, Yu Wang, Dingzhi Huang, Peng Chen, Hua Guo Abstract Background: Malignant pleural mesothelioma (MPM) is a rare type of tumor closely associated with asbestos exposure. Increasing evidence shows that high immuno-heterogeneity reduces the therapeutic…
Read More
Skip to content